GLP-1 Non-Responders: What to Do If the Drug Isn't Working

What counts as a non-response

No universally agreed definition exists, but clinical practice and payer guidelines commonly use:

Inadequate response: Less than 4–5% total body weight loss at 12 weeks on an adequate dose

Clinical trial definition: STEP trials used 5% at week 16 as a cut-off below which response was considered inadequate for continued prescribing

Real-world prescribing: Many insurance policies require at least 5% weight loss at 12 weeks to continue coverage

The key question when loss is below these thresholds: is this a true pharmacological non-response, or an inadequate treatment situation that can be corrected?

The most common reasons for inadequate response (that are correctable)

1. Still on a sub-therapeutic dose

The most common reason for low early response. The dose escalation protocol means most patients are not at a therapeutic dose until weeks 5–17:

• Semaglutide: therapeutic threshold is approximately 1 mg (week 9)
• Tirzepatide: therapeutic threshold is approximately 5–7.5 mg (weeks 5–12)

A patient reporting "I've been on it for 3 months and nothing is happening" who is still at 0.5 mg semaglutide or 5 mg tirzepatide may simply be under-dosed for their individual needs. Escalation to the next dose step is the first intervention.

2. Caloric compensation

GLP-1 drugs reduce appetite, but they do not prevent eating. Some patients — particularly those with highly-developed eating habits or emotional eating patterns — consciously or unconsciously eat through the appetite suppression. They may eat more frequent small meals, choose calorically dense foods, or continue eating when no longer hungry.

Signs of caloric compensation: Scale not moving despite feeling appetite suppression; high nausea (which resolves when the food that triggered it is eliminated, but eating continues).

Intervention: Brief food tracking (1–2 weeks) to establish whether caloric intake is actually reduced. If not, nutritional counselling.

3. Medication interactions

Several medications can counteract GLP-1 effectiveness:

• Corticosteroids (prednisone, etc.): Cause insulin resistance and weight gain that can offset GLP-1 effects
• Antipsychotic medications (olanzapine, quetiapine, clozapine): Associated with significant weight gain that is often resistant to GLP-1 therapy
• Anticonvulsants (valproate, gabapentin): Can cause weight gain
• Certain antidepressants (mirtazapine, paroxetine): Weight-promoting effects

If on any of these medications, the prescribing physician should review whether alternatives exist that are weight-neutral or weight-friendly.

4. Underlying thyroid dysfunction

Untreated hypothyroidism causes weight gain and is sometimes discovered when GLP-1 therapy is initiated. TSH should be checked if not done recently — the STEP trials excluded patients with thyroid disorders, and thyroid dysfunction is prevalent in obese populations.

5. Inadequate sleep

Short sleep duration is associated with increased appetite, reduced leptin, elevated ghrelin, and reduced insulin sensitivity — all of which counteract GLP-1 therapy. Less than 6 hours of sleep per night can substantially attenuate GLP-1 weight loss outcomes.

6. Compounded formulation quality issues

Patients on compounded semaglutide who are not losing weight should consider whether the formulation is correctly potent. Compounded semaglutide quality varies — underdosing due to manufacturing errors or incorrect formulation is possible. Requesting a COA (certificate of analysis) from the compounding pharmacy and confirming the stated dose matches the administration volume is appropriate.

Signs of genuine pharmacological non-response

True pharmacological non-response (poor drug efficacy regardless of dose) exists but is less common than correctable non-response. Signs include:

• No appetite suppression even at maximum dose (complete absence of the subjective drug effect)
• No reduction in food noise
• No GI side effects whatsoever (some degree of GI effect is expected as a marker that the drug is active)

Genuine non-response may relate to pharmacogenomic variations in GLP-1 receptor expression, receptor polymorphisms, or downstream signalling differences. This is an active research area.

What to try if you are not responding adequately

Step 1: Rule out correctable causes

• Is the dose actually therapeutic (at least 1 mg semaglutide or 7.5 mg tirzepatide)?
• Is caloric intake actually reduced (tracked for 1 week)?
• Are any weight-gain-promoting medications being taken?
• Has thyroid function been tested?
• Is sleep adequate (7+ hours)?

Step 2: Escalate dose

If below maximum dose and the above factors are addressed, escalate to the next dose step. Many patients who respond poorly at 1 mg semaglutide respond well at 1.7–2.4 mg.

Step 3: Switch drugs

If maximum dose of semaglutide is tolerated but producing inadequate response, switching to tirzepatide is the most evidence-based next step. SURMOUNT-5 showed tirzepatide produces approximately 47% more weight loss than semaglutide in a direct comparison. Some semaglutide non-responders do respond to tirzepatide.

Step 4: Add behavioural/dietary intervention

Some insurance protocols and clinical guidelines require structured dietary or behavioural programme participation for continued prescribing. Even without insurance requirements, GLP-1 therapy in combination with dietitian support produces better outcomes than drug alone.

Step 5: Evaluate for bariatric surgery

For patients with BMI ≥40 who have tried maximum doses of at least two GLP-1 drugs without adequate response, bariatric surgery (gastric bypass or sleeve gastrectomy) produces larger and more durable weight loss than pharmacological therapy for this subpopulation.

The 5% rule: when insurance stops covering

Many insurance policies use a 5% weight loss at 12–16 weeks rule for continued coverage. This creates a specific clinical situation: patients who are 3–4% down at week 12, just below the threshold, risk losing coverage.

The important context for these patients:

• Week 12 is during dose escalation — not a meaningful efficacy assessment point
• 5% at 16+ weeks is more appropriate than 5% at 12 weeks
• Insurance criteria are not the same as clinical efficacy criteria
• An appeal is often appropriate if a patient is showing directional response but hasn't crossed the threshold

Summary

Inadequate GLP-1 response is most commonly correctable — through dose escalation, caloric compensation identification, addressing medication interactions, or checking thyroid function. True pharmacological non-response exists but is less common. The clinical response pathway: rule out correctable causes → escalate dose → switch to tirzepatide → add structured dietary support → evaluate bariatric surgery for high-BMI non-responders. Insurance coverage cutoffs at 12 weeks are not the same as clinical efficacy — borderline patients should appeal rather than automatically accept denial.